The United Kingdom and the United States have concluded a important trade agreement that will keep no import taxes on UK medicine shipments going into the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to boost funding on drugs through the NHS. This pledge ensures that import taxes on these crucial products will stay at nothing for a timeframe of three years.
This deal follows recent threats to hike tariffs on branded pharmaceutical imports, with figures mentioned reaching 100%.
"This agreement with the UK bolsters the global environment for innovative medicines and establishes long-overdue balance to transatlantic drug exports," a release declared.
Commercial Importance
Drugs are one of the the United Kingdom's biggest export categories to the America, which is by far the primary destination for major UK drugmakers.
Export figures show that in the one-year period to the end of last September, the UK exported pharmaceutical products worth billions to the US. This value accounted for nearly one-fifth of all goods exports in that timeframe.
"This agreement protects employment, increases investment and facilitates the UK to establish itself as a worldwide center for medical research," a minister commented.
Key British Pledges
The pact includes several notable commitments from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must refund to the NHS to stay within budget will be capped at 15%. Previously, refunds were more than 20%.
Broader Context
The deal comes amid a ongoing row between the sector and the British authorities over drug pricing and approval rates.
This friction were intensified by arguments that American patients were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward American operations.
One official publicly accepted that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had declined as a percentage of its overall budget over the previous ten-year period.
